Cargando…

Time-dependent endpoints as predictors of overall survival in multiple myeloma

BACKGROUND: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Félix, Jorge, Aragão, Filipa, Almeida, João M, Calado, Frederico JM, Ferreira, Diana, Parreira, António BS, Rodrigues, Ricardo, Rijo, João FR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607860/
https://www.ncbi.nlm.nih.gov/pubmed/23497363
http://dx.doi.org/10.1186/1471-2407-13-122
_version_ 1782264155781201920
author Félix, Jorge
Aragão, Filipa
Almeida, João M
Calado, Frederico JM
Ferreira, Diana
Parreira, António BS
Rodrigues, Ricardo
Rijo, João FR
author_facet Félix, Jorge
Aragão, Filipa
Almeida, João M
Calado, Frederico JM
Ferreira, Diana
Parreira, António BS
Rodrigues, Ricardo
Rijo, João FR
author_sort Félix, Jorge
collection PubMed
description BACKGROUND: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. METHODS: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman’s rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. RESULTS: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7–3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. CONCLUSION: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation.
format Online
Article
Text
id pubmed-3607860
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36078602013-03-27 Time-dependent endpoints as predictors of overall survival in multiple myeloma Félix, Jorge Aragão, Filipa Almeida, João M Calado, Frederico JM Ferreira, Diana Parreira, António BS Rodrigues, Ricardo Rijo, João FR BMC Cancer Research Article BACKGROUND: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. METHODS: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman’s rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. RESULTS: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7–3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. CONCLUSION: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation. BioMed Central 2013-03-16 /pmc/articles/PMC3607860/ /pubmed/23497363 http://dx.doi.org/10.1186/1471-2407-13-122 Text en Copyright ©2013 Félix et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Félix, Jorge
Aragão, Filipa
Almeida, João M
Calado, Frederico JM
Ferreira, Diana
Parreira, António BS
Rodrigues, Ricardo
Rijo, João FR
Time-dependent endpoints as predictors of overall survival in multiple myeloma
title Time-dependent endpoints as predictors of overall survival in multiple myeloma
title_full Time-dependent endpoints as predictors of overall survival in multiple myeloma
title_fullStr Time-dependent endpoints as predictors of overall survival in multiple myeloma
title_full_unstemmed Time-dependent endpoints as predictors of overall survival in multiple myeloma
title_short Time-dependent endpoints as predictors of overall survival in multiple myeloma
title_sort time-dependent endpoints as predictors of overall survival in multiple myeloma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607860/
https://www.ncbi.nlm.nih.gov/pubmed/23497363
http://dx.doi.org/10.1186/1471-2407-13-122
work_keys_str_mv AT felixjorge timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT aragaofilipa timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT almeidajoaom timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT caladofredericojm timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT ferreiradiana timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT parreiraantoniobs timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT rodriguesricardo timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma
AT rijojoaofr timedependentendpointsaspredictorsofoverallsurvivalinmultiplemyeloma